Equities analysts expect Gamida Cell Ltd (NASDAQ:GMDA) to report earnings per share (EPS) of ($0.29) for the current quarter, according to Zacks. Zero analysts have provided estimates for Gamida Cell’s earnings, with estimates ranging from ($0.32) to ($0.26). Gamida Cell posted earnings of ($0.30) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 3.3%. The business is expected to report its next earnings report on Wednesday, November 11th.
According to Zacks, analysts expect that Gamida Cell will report full-year earnings of ($1.29) per share for the current financial year, with EPS estimates ranging from ($1.40) to ($1.19). For the next fiscal year, analysts expect that the business will report earnings of ($1.14) per share, with EPS estimates ranging from ($1.32) to ($0.89). Zacks’ EPS calculations are an average based on a survey of research firms that follow Gamida Cell.
Gamida Cell (NASDAQ:GMDA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.11).
Several institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC boosted its holdings in shares of Gamida Cell by 73.4% in the 2nd quarter. FMR LLC now owns 4,900,426 shares of the company’s stock worth $22,395,000 after purchasing an additional 2,073,885 shares in the last quarter. BVF Inc. IL boosted its holdings in shares of Gamida Cell by 114.4% in the 2nd quarter. BVF Inc. IL now owns 2,143,667 shares of the company’s stock worth $9,797,000 after purchasing an additional 1,143,667 shares in the last quarter. Driehaus Capital Management LLC purchased a new position in shares of Gamida Cell in the 2nd quarter worth about $8,732,000. Federated Hermes Inc. purchased a new position in shares of Gamida Cell in the 2nd quarter worth about $8,124,000. Finally, Alyeska Investment Group L.P. boosted its holdings in shares of Gamida Cell by 412.8% in the 2nd quarter. Alyeska Investment Group L.P. now owns 1,097,151 shares of the company’s stock worth $5,014,000 after purchasing an additional 883,198 shares in the last quarter. Hedge funds and other institutional investors own 66.24% of the company’s stock.
Shares of GMDA traded up $0.14 during mid-day trading on Friday, hitting $4.25. The stock had a trading volume of 76,986 shares, compared to its average volume of 188,511. The firm has a market cap of $102.94 million, a P/E ratio of -2.97 and a beta of 1.93. The business has a fifty day moving average price of $4.22 and a 200-day moving average price of $4.31. The company has a debt-to-equity ratio of 0.08, a current ratio of 6.69 and a quick ratio of 6.69. Gamida Cell has a 52 week low of $2.60 and a 52 week high of $7.70.
About Gamida Cell
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia.
Further Reading: How does a reverse stock split work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.